Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part Phase 1 Open-label Safety and Pharmacokinetic Study of Intravenous RC220 in Combination With Doxorubicin in Adult Patients With Solid Tumours.

NCT06815575 is registered in ClinicalTrials.gov with Racura Oncology Ltd as lead sponsor.

NCT NCT06815575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06815575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part Phase 1 Open-label Safety and Pharmacokinetic Study of Intravenous RC220 in Combination With Doxorubicin in Adult Patients With Solid Tumours.
Lead sponsor
Racura Oncology Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
April 2, 2025
Completion date
January 31, 2029
Enrollment
53 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumours, solid tumours